Methylational urinalysis: A prospective study of bladder cancer patients and age stratified benign controls

Oncogene

Volumn 25, Issue 13, 2006, Pages 1984-1988

  Yates, D R ^a   Rehman, I ^a   Meuth, M ^a   Cross, S S ^a   Hamdy, F C ^a   Catto, J W F ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; DNA methylation; Epigenetic; Urinalysis

Indexed keywords

APC PROTEIN; DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UVOMORULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BENIGN TUMOR; BLADDER CANCER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE FREQUENCY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; URINALYSIS;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 33645318692     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209209     Document Type: Article

References (20)

1. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. (1998). Cancer Res 58: 5489-5494.
2. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E. (2001). Am J Pathol 159: 831-835.
3. Brown FM. (2001). Urol Clin N Am 27: 25-37.
4. Catto JWF, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N et al. (2005). J Clin Oncol 23: 2903-2910.
5. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL et al. (2002). Clin Cancer Res 8: 464-470.
6. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. (2004). Clin Cancer Res 10: 1887-1893.
7. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonnzalogo ML et al. (2004). Clin Cancer Res 10: 7457-7465.
8. Greenlee R, Hill-Harmon MB, Murray T, Thun M. (2001). CA Cancer J Clin 51: 15.
9. Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S et al. (2001). Oncogene 20: 531-537.
10. Harnden SV, Tokumaru Y, Westra W, Goodman S, Ahrendt SA, Yang SC et al. (2003). Clin Cancer Res 9: 370-375.
11. Herman JG, Baylin SB. (2003). N Engl J Med 349: 2042-2054.
12. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Proc Natl Acad Sci USA 93: 9821-9826.
13. Issa JP. (2004). Crit Rev Oncol Hematol 32: 31-43.
14. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. (1994). Nat Genet 7: 536-540.
15. Laird PW. (2003). Nature Rev 3: 253-266.
16. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S et al. (2001). Cancer Res 61: 8659-8663.
17. Molinie V, Longchampt E, Ouazana D, Lebret T. (2001). Ann Pathol 23: 306-331.
18. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. (1997). Nat Med 3: 621-624.
19. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. (1999). Proc Natl Acad Sci USA 96: 8681-8686.
20. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J et al. (2002). Cancer Research 62: 371-375.